If Oxy ANDA gets rejected, if profitability is uglier than anticipated while R&D pipeline takes its own sweet time would be just a few simple reasons share price would drop. These are realistic, however, so is a potential Oxy filing acceptance for review, Dexcel movement, better IR & ER market penetration, optimizing sales & marketing team, positive BE studies and subsequent filings, etc. Let’s see how creative management can be besides their uncanny ability to keep Mikah around.
News 
Market Data 
Discover 
